Long-Term ERLEADA® (apalutamide) Patient-Reported Outcomes Data in Metastatic Hormone-Sensitive Prostate Cancer Demonstrate Maintenance of Health-Related Quality of Life for Patients
- EMEA Innovative Medicine
- Long-Term ERLEADA® (apalutamide) Patient-Reported Outcomes Data in Metastatic Hormone-Sensitive Prostate Cancer Demonstrate Maintenance of Health-Related Quality of Life for Patients
Long-Term ERLEADA® (apalutamide) Patient-Reported Outcomes Data in Metastatic Hormone-Sensitive Prostate Cancer Demonstrate Maintenance of Health-Related Quality of Life for Patients
- X (Twitter)
Copy link